Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 10Other hematologic neoplasm 5Dermatologic 3Other solid neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Neoplasm of Uncertain Malignant Potential 1

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × peginterferon alfa-2a × Other solid neoplasm × Clear all
NCT00253474 2012-03-29

PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
36 enrolled
Other solid neoplasm

Neoplasm of Uncertain Malignant Potential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡